Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Doxycycline for Tick-Borne Disease in Dogs and Cats: Ehrlichia, Anaplasma, RMSF, and Lyme
Doxycycline 10 mg/kg/day for 28 days treats all major tick-borne infections in dogs and cats; short courses risk recrudescence. Esophageal stricture ris...
Read →Phenobarbital for Canine Idiopathic Epilepsy: Prescribing Patterns, Pharmacometrics, and TDM
Phenobarbital remains the most-prescribed first-line ASD for canine idiopathic epilepsy (34.9% in US primary care). A 2025 population PK model enables precision dosing, while TDM to a 20-35 ug/mL target stays essential and is itself assay-dependent.
Read →Canine Parvovirus Enteritis in Dogs: Pathophysiology, Diagnosis, and Evidence-Based Management
An evidence-based clinical reference on canine parvovirus (CPV-2) enteritis: diagnosis, supportive-care standard of care, CPMA (Trutect) efficacy and dosing, outpatient protocols, and post-prophylaxis vaccine timing.
Read →Prednisolone and Prednisone in Dogs and Cats: Pharmacology, Dosing, and Adverse Effect Management
Prednisolone is the preferred oral glucocorticoid in cats (~100% bioavailability vs ~21% for prednisone), while dogs treat the two as equivalent. A clinician-facing evidence summary of dosing, tapering, adverse effects, and steroid-sparing agents across dogs and cats.
Read →Methimazole and Carbimazole for Feline Hyperthyroidism: Pharmacology, Dosing, and Adverse Effect Management
Methimazole 1.25-2.5 mg PO BID is the standard medical therapy for feline hyperthyroidism, controlling but not curing disease. This hub consolidates dosing, adverse-effect management, carbimazole and transdermal options, and how medical management compares with radioiodine, iodine-restricted diet, and surgery — including the concurrent-CKD reversibility trial.
Read →Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety
Velagliflozin (Senvelgo) is a once-daily oral SGLT2 inhibitor for the insulin-naive diabetic cat: the SENSATION trial (n=252) cut median blood glucose from 436 to 125 mg/dL by day 180. This hub covers efficacy, the euglycemic DKA hazard, mandatory BHB monitoring, patient selection, and how it compares with bexagliflozin and insulin.
Read →Robenacoxib for Feline Musculoskeletal Pain: COX-2 Selectivity, DJD Evidence, Safety, and the ISFM/AAFP Framework
The evergreen clinical hub on robenacoxib (Onsior) for feline musculoskeletal and DJD pain: COX-2 tissue selectivity and PK, the Adrian 2021 pilot RCT (49% disability reduction, NNT 3.8), King 2021 pooled chronic safety with a CKD subgroup, grapiprant comparator and NSAID-timing data, and the 2024 ISFM/AAFP monitoring framework.
Read →Pimobendan for Canine Myxomatous Mitral Valve Disease (MMVD): Evidence, Mechanism, and Use
Pimobendan's dual calcium-sensitizer and PDE3-inhibitor mechanism, the EPIC and QUEST pivotal trials, 2019 ACVIM staging, PROTECT DCM data, and the 2024-2026 reverse-remodeling evidence that says document baseline echo before you dose a Stage B2 dog.
Read →Sarolaner for Canine Generalized Demodicosis: Efficacy, Class Pharmacology, and Safety
Oral sarolaner-based isoxazolines clear Demodex canis in generalized demodicosis: a masked field study reached 100% mite reduction by Day 90.
Read →Cannabidiol (CBD) for Canine Idiopathic Epilepsy: What the Controlled Trials Show
Two randomized trials and a pilot cohort show CBD added to antiseizure drugs modestly cuts seizure frequency in dogs, but not the 50%-responder rate; ALP rises consistently, so monitor the liver and watch CYP450 interactions.
Read →Levetiracetam for Canine Idiopathic Epilepsy: Comparative Outcomes, Serum Monitoring, and Intranasal Emergency Use
Evidence review of levetiracetam for canine idiopathic epilepsy: outcomes similar to zonisamide and phenobarbital with fewer adverse effects, the phenobarbital serum interaction, intranasal emergency PK, and the class-level weight-gain effect. Includes rTMS and metabolic adjuncts for drug-resistant cases.
Read →Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Drug Interactions
Evidence-based review for DVMs: the 2018 ACVIM consensus reshaped omeprazole prescribing, yet a 265-vet survey shows persistent overprescription; long-term use raises gastrin without cobalamin change, and the feline clopidogrel interaction is PK-real but PD-limited.
Read →